Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2652W HIGH $4.78
Volume
23.06 K
Value Traded
55.39 K
Short % Float
3.53%
-3.08%Week
-3.35%1 Month
+860.58%3 Month
+801.04%6 Month
-97.15%5 Year
-97.69%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.54 M
EPS (TTM)
-0.93
P/E Ratio
-
Ent. Value
3.04 M
Total Shares
1.89 M
Float Shares
1.48 M
Insiders
21.82%
Institutions
8.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CLGN Catalyst Timeline
Dated clinical, regulatory and corporate events for CollPlant Biotechnologies Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CollPlant Biotechnologies Ltd.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
▼Equity OfferingCorporate
Private placement of ordinary shares and warrants for $2.6 million gross proceeds
Past FDA Catalysts and PDUFA Decisions
How CLGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
CollPlant Biotechnologies Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CLGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Collink.3D™ | tissue engineering and regenerative medicine | 2025-10-20 | enhanced mechanical strength; elasticity; stabilityRead More | CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of TechnologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CLGN for Q2 2026. | ||||
CLGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLGN ranks across every disease it competes in
Competitive Position is a premium feature
See how CLGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLGN News
CLGN▲ +3.8%today
LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations
CollPlant's subsidiary, LightSolver, has filed a provisional patent application to enhance its photonic computing platform. The application introduces a method for solving complex physical and engineering problems, expanding the range of simulations the platform can handle. This move is part of LightSolver's strategy to strengthen its intellectual property and broaden its technological applications.
Read more →CLGN▼ -5.6%on this newsshared move
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported its second quarter financial results for 2026, highlighting the acquisition of LightSolver, which enhances its technology portfolio in high-performance computing. The company experienced a decrease in revenues and an increase in gross loss compared to the previous year. Despite these challenges, CollPlant remains focused on advancing its regenerative medicine initiatives and establishing strategic partnerships.
Read more →CLGNLightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads
CollPlant's subsidiary, LightSolver, in collaboration with HLRS, published a study showcasing the advantages of its Laser Processing Unit (LPU) in high-performance computing. The research indicates that the LPU can significantly reduce time-to-solution for complex computational problems, outperforming traditional GPU algorithms. This advancement highlights the potential of photonic computing in future hybrid architectures.
Read more →CLGNCollPlant to Host LightSolver Investor Webinar on September 17, 2026
CollPlant Biotechnologies Ltd. announced that its subsidiary, LightSolver, will host an investor webinar on September 17, 2026. The webinar will cover LightSolver's photonic computing technology and its roadmap for commercialization. This event follows CollPlant's strategic acquisition of LightSolver, marking a significant expansion into advanced computing.
Read more →CLGN▼ -7.9%on this news
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
CollPlant Biotechnologies Ltd. announced a one-for-ten reverse share split effective September 4, 2026, following shareholder approval. This move aims to help the company comply with Nasdaq's minimum bid price requirements. The split will adjust the number of outstanding shares and the exercise price of warrants and options accordingly.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
CollPlant Biotechnologies has announced a definitive agreement for a private placement, raising approximately $2.6 million through the sale of ordinary shares and warrants. The funds will be used for general corporate purposes, including R&D and potential strategic transactions. The placement is expected to close by July 1, 2026, pending customary conditions.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported its financial results for Q1 2026, revealing a significant revenue decline and increased net losses compared to Q1 2025. The company is pursuing collaborations in medical aesthetics and has made progress in the development of next-generation dermal fillers. Additionally, it launched BioFlex, a rhCollagen-based kit for bioprinting. However, the financial outlook is strained, reflected in increased operational losses and cash usage.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies has announced its financial results for the first quarter of 2026, highlighting its ongoing commitment to developing innovative products based on recombinant human collagen. The company continues to focus on applications in tissue regeneration and medical aesthetics. This update reflects CollPlant's strategic direction and financial health.
Read more →CLGN▼ -15.7%on this news
Letter to Shareholders Collaborations As noted, Allergan Industrie SAS, an AbbVie company, notified us that it was exercising its right to terminate the development agreement, previously entered into in February 2021 , u
CollPlant has announced the termination of its development agreement with AbbVie, signaling a potential shift in strategy. The company remains optimistic about future opportunities in the aesthetics market, particularly focusing on its rhCollagen technology for dermal and soft tissue fillers. Despite the workforce reduction as part of a cost-optimization plan, CollPlant is actively seeking new strategic partners and planning clinical trials for its innovative products. The company emphasizes its commitment to growth and is confident about extending its cash runway into 2026.
Read more →CLGN▼ -15.7%on this news
CollPlant Issues Letter to Shareholders
CollPlant announced the termination of its development agreement with AbbVie, viewing it as a new opportunity. The company is pursuing partnerships for aesthetic products and implementing cost-reduction measures, including a significant workforce reduction. CollPlant aims to advance its innovative technologies in dermal fillers and breast implants while extending its cash runway into late 2026.
Read more →CLGN▼ -12%on this news· ran to -29% by day 3
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported its 2025 financial results, showcasing significant progress in its regenerative and aesthetic medicine technologies. The company achieved a development milestone that facilitated a $2 million payment from AbbVie, expanded its distribution network into North America, and advanced its proprietary product line. Noteworthy achievements included the successful results from clinical trials of regenerative breast implants, and the development of a humanized 3D bioprinted skin model by Mayo Clinic using CollPlant's rhCollagen technology. Additionally, the company secured new patents related to its dermal filler technology, enhancing its intellectual property portfolio.
Read more →CLGN▲ +17.1%on this newsshared move
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
CollPlant Biotechnologies received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock price has been below $1.00 for 30 consecutive days. The company has a 180-day compliance period to regain compliance, with the option for a second period if necessary. During this time, its shares will continue to trade on Nasdaq.
Read more →CLGNCollPlant Biotechnologies Launches Redesigned Corporate Website
CollPlant Biotechnologies has launched a redesigned corporate website aimed at improving transparency and accessibility for investors and partners. The new platform features comprehensive information on the company's proprietary rhCollagen technology, product pipeline, and strategic collaborations. According to CEO Yehiel Tal, the update reflects the company's commitment to advancing in the regenerative medicine and aesthetics sectors, with a focus on enhancing stakeholder engagement. The website will serve as a central resource for CollPlant's scientific programs and corporate updates.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS
CollPlant Biotechnologies has announced that it will release its financial results for the full year of 2025 on March 26, 2026, prior to the opening of U.S. markets. As a leader in regenerative and aesthetic medicine, CollPlant focuses on developing products based on non-animal-derived collagen. The company has a notable partnership with Allergan for the global commercialization of dermal fillers. This financial announcement highlights the company's ongoing progress and contributions to the fields of tissue regeneration and aesthetics.
Read more →CLGNCollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
CollPlant Biotechnologies has secured a patent allowance from the Korean Patent Office for its innovative photocurable dermal filler technology. This patent covers a polymerizable solution used for tissue augmentation, enhancing the company's intellectual property in the aesthetic market. CEO Yehiel Tal emphasized the strategic importance of this patent for expanding their rhCollagen platform in high-value markets. The technology aims to provide long-term contour stability and tissue integration.
Read more →CLGNCollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
CollPlant has launched BioFlex, a ready-to-print rhCollagen-based kit for Digital Light Processing 3D bioprinting. This innovative solution is designed to facilitate the biofabrication of advanced tissue models and engineered organs, significantly reducing development time. BioFlex integrates biodegradable polymers and photoactive agents, enabling precise fabrication of complex structures. The product aims to empower researchers in biopharma and academia with high-performance bioprinting solutions.
Read more →CLGN▼ -11.9%on this news
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
CollPlant Biotechnologies announced a strategic focus on addressing facial volume loss in patients using GLP-1 weight-loss therapies. The company is advancing its photocurable dermal filler technology, which aims to restore facial structure and skin quality through a supportive regenerative matrix. With the rising adoption of GLP-1 treatments, CollPlant positions itself to meet the growing aesthetic needs for patients experiencing rapid weight loss. The technology is currently in preclinical development and aims to combine immediate structure restoration with long-term tissue improvement.
Read more →CLGN▼ -53.4%on this news
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
CollPlant Biotechnologies has announced a registered direct offering of 1.6 million ordinary shares at $1.25 each, aiming to raise approximately $2 million. The proceeds will be utilized for general corporate purposes, including research and development. The offering is expected to close on February 6, 2026, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.
Read more →CLGN▼ -53.4%on this newsshared move
CollPlant BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
CollPlant Biotechnologies announced a definitive agreement for a registered direct offering of 1,600,000 ordinary shares at a price of $1.25 each, aiming to raise approximately $2.0 million. The funding will be utilized for general corporate purposes, including research and development activities. Concurrently, the company will issue unregistered series A and B warrants for the shares. The offering is expected to close on or about February 6, 2026, subject to customary closing conditions.
Read more →About CollPlant Biotechnologies Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next CLGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime